NCT03520686 Phase 3 Terminated
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer Study sponsor: ImmunityBio, Inc. · IBRX
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2025-10-13 Actual
Enrollment · participants 102 Actual
Source updated 2026-05-26 Last update listed in the registry record
Version history
Changes to this trial Last 12 months Posted 2026-04-15 · 5 fields changed
Participant count type Recorded edit − Previous value Estimated
Enrollment · participant count Recorded edit − Previous value count: 1538; type: ESTIMATED
+ Updated value count: 102; type: ACTUAL
Completion date type Recorded edit − Previous value Estimated
Primary completion date Recorded edit − Previous value 2026-10-31
+ Updated value 2025-10-13
Recruitment status Recorded edit − Previous value Active not recruiting
+ Updated value Terminated
Check registry source Posted 2025-10-16 · 1 field changed
Primary completion date Recorded edit − Previous value 2025-10-01
+ Updated value 2026-10-31
Check registry source Posted 2025-10-09 · 1 field changed
Primary outcomes · main study measures Text edit · unverified significance − Previous value measure: Progression Free Survival (PFS)
+ Updated value measure: Progression Free Survival (PFS); measure: Change in absolute lymphocyte count (ALC).
The saved outcome text may be shortened. Check the source for full wording.
Check registry source This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial